OMKARCHEM share price & results
- Mar 2026
- Jun 2026
Badlapur (Maharashtra) manufacturer of specialty chemicals and intermediates — Iodine and Selenium derivatives, API intermediates and resolving agents — across 8 units, exporting to 38+ countries.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.01 | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. No quarter a year earlier is in the series, so no change is shown. | |
| Operating margin | -1800.0 | Operating profit / revenue | Quarter to Mar 2026 | For the quarter; a change is in percentage points. No quarter a year earlier is in the series, so no change is shown. | |
| Net profit | -0.33 | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. No quarter a year earlier is in the series, so no change is shown. | |
| Return on equity | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. | ||
| Free cash flow margin | Fiscal year | FY · period unavailable | Not in the analysed materials. No older figure is substituted. | ||
| Revenue growth (YoY) | Trailing twelve months | TTM · period unavailable | Not in the analysed materials. No older figure is substituted. |
Price
Performance −44.2% 1Y
1Y: ₹6.11 on 25 Apr 2025 → ₹3.41. High ₹7.81 (5 Jun 2025), low ₹3.41 (28 Apr 2026).
- Previous close
- ₹3.58
- Market cap
- ₹7 Cr
- 52-week range
- ₹3.41 – ₹7.81
- One year
- −43.07%
Overview
- Symbol
- NSE:OMKARCHEM
- Sector
- Chemicals
- Industry
- Commodities
- Exchange
- NSE
- Currency
- INR
What OMKARCHEM does
Based on the company's own presentations, annual report and earnings calls.
Omkar Speciality Chemicals Limited manufactures specialty chemicals and intermediates for the chemical and allied industries, with product lines spanning API intermediates, Iodine Derivatives, Selenium Derivatives, Resolving Agents and other specialty intermediates. Manufacturing is spread across 8 units — four in Badlapur (Thane) and the rest in Chiplun, Ratnagiri and Mahad, Maharashtra — backed by an in-house R&D centre focused on new product development and continuous process upgradation. The company exports to more than 38 countries across Europe, Canada, Asia, South America and Australia. Its erstwhile Veterinary API business was demerged in 2016 into a separately listed entity, Lasa Supergenerics Ltd (later renamed Lasa Laboratories Ltd).
Segments
- API Intermediates
- Specialty Chemical Intermediates
- Iodine Derivatives
- Selenium Derivatives
- Resolving Agents
- Manufacturing units
- 8 (4 in Badlapur; others in Chiplun, Ratnagiri and Mahad, Maharashtra)
- Export reach
- 38+ countries across Europe, Canada, Asia, South America & Australia
- Permanent employees
- 55 (manufacturing plants + administrative office, FY21)
- Product segments
- 5 (API, Intermediates, Iodine Derivatives, Selenium Derivatives, Resolving Agents)
- R&D centre
- 1 in-house (new product development & process upgradation)
- Regulatory oversight
- Facilities audited by FDA, MPCB, Department of Explosives
Fundamentals
Ratios, each with its period
Financials
What the filings say
Net profit, against the quarter before: 0% (quarter to mar 2026 against dec 2025).
| Line item | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4 | 6 | 5 | 4 | 0 | 0 | 0 | 0 |
| Expenses | 7 | 6 | 8 | 5 | 0 | 0 | 0 | 0 |
| Operating profit | -2 | 0 | -3 | -1 | -0 | -0 | -0 | -0 |
| Operating margin | −54.9% | 2.0% | −61.6% | −25.4% | −1900.0% | −362.5% | — | −1800.0% |
| Other income | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 1 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -4 | -2 | -5 | -3 | -0 | -1 | -0 | -0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -4 | -2 | -5 | -3 | -0 | -1 | -0 | -0 |
| EPS (₹ per share) | -1.73 | -0.89 | -2.39 | -1.41 | -0.20 | -0.25 | -0.16 | -0.16 |
| Line item | Mar 2015 | Mar 2016 | Mar 2021 | Mar 2022 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 266 | 412 | 45 | 23 | 0 |
| Expenses | 213 | 333 | 39 | 29 | 1 |
| Operating profit | 52 | 81 | 6 | -6 | -1 |
| Other income | 0 | 0 | 6 | 1 | 0 |
| Interest | 15 | 20 | 6 | 6 | 0 |
| Depreciation | 10 | 9 | 4 | 2 | 1 |
| Profit before tax | 28 | 52 | 3 | -13 | -2 |
| Net profit | 23 | 30 | 2 | -13 | -2 |
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 21 | 21 | 21 | 21 | — | 21 |
| Reserves | -169 | -183 | -179 | -192 | — | -2 |
| Borrowings | 230 | 233 | 228 | 226 | — | 3 |
| Other liabilities | 26 | 26 | 17 | 18 | — | 24 |
| Total liabilities | 107 | 97 | 86 | 72 | — | 46 |
| Fixed assets | 68 | 53 | 28 | 26 | — | 19 |
| Capital work in progress | 0 | 0 | 0 | 0 | — | 0 |
| Investments | 0 | 0 | 1 | 0 | — | 0 |
| Other assets | 38 | 44 | 58 | 46 | — | 26 |
| Total assets | 107 | 97 | 86 | 72 | — | 46 |
| Line item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|
| Cash from operations | -14 | 11 | -9 | 29 | 81 | 67 |
| Cash from investing | -25 | -63 | -42 | -61 | -94 | -46 |
| Cash from financing | 80 | 43 | 43 | 30 | 10 | -26 |
| Net cash flow | 41 | -9 | -9 | -2 | -3 | -5 |
| Free cash flow | -39 | -53 | -52 | -34 | -13 | 21 |
| Line item | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 |
|---|---|---|---|---|---|---|
| Debtor days | 93 | 84 | 114 | 143 | 106 | 115 |
| Inventory days | 148 | 168 | 190 | 191 | 193 | 126 |
| Days payable | 105 | 80 | 95 | 102 | 134 | 124 |
| Cash conversion cycle | 136 | 173 | 209 | 232 | 165 | 117 |
| Working capital days | 70 | 3 | 39 | -5 | -77 | -15 |
| Return on capital employed | — | 18.0% | 16.0% | 11.0% | 12.0% | 18.0% |
| Dividend payout | 19.0% | 15.0% | 14.0% | 22.0% | 13.0% | 10.0% |
Ownership
Who owns it
Promoters hold 95.00% as of Jun 2026; institutions cut 0.73 pts since Mar 2026.
- Promoters 95.00%
- Foreign institutions 0.00%
- Domestic institutions 0.00%
- Public 5.00%
Who is on the register
Named in the Jun 2026 filing
Every holder of OMKARCHEM above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| — | off the list | |
| — | off the list | |
| — | off the list |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for OMKARCHEM
Free account: one company. Everything above stays public.
Write why you follow OMKARCHEM and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Chemicals companies
- VS
VSCLVadivarhe Speciality Chemicals Ltd - BO
BOHRAINDBohra Industries Limited - NO
NOLNational Oxygen Ltd. - AR
ARUNAYAArunaya Organics Ltd - TE
TECILCHEMTECIL Chemicals and Hydro Power Limited - SA
SAROJASaroja Pharma Industries India Ltd - YC
YCCLYasons Chemex Care Limited - RI
RITEZONERite Zone Chemcon India Limited
Learn to analyse OMKARCHEM
Guides on how to read this kind of business and the numbers that matter.